NEVIRAPINE PHARMACOKINETICS IN PREGNANT WOMEN AND IN THEIR INFANTS AFTER IN UTERO EXPOSURE
- 1 August 2001
- journal article
- clinical trial
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 20 (8), 803-805
- https://doi.org/10.1097/00006454-200108000-00017
Abstract
The safety, toxicity and pharmacokinetics of nevirapine were studied in HIV-infected pregnant women beginning chronic therapy late in the third trimester and in their infants. Initial dose pharmacokinetic profiles in the pregnant women were similar to those seen in nonpregnant adults. Serum nevirapine concentrations fell below the 100-ng/ml target concentration by Day 7 of life in four infants, suggesting that nevirapine elimination is accelerated in these infants compared with newborns whose mothers receive only a single intrapartum nevirapine dose.Keywords
This publication has 4 references indexed in Scilit:
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 1999
- A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006)AIDS, 1999
- Pharmacokinetics of Nevirapine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their NeonatesThe Journal of Infectious Diseases, 1998
- Drug Evaluations Anti-infectives: Nevirapine: A review of its development, pharmacological profile and potential for clinical useExpert Opinion on Investigational Drugs, 1996